In a prospective phase II trial, pembrolizumab, which is an anti-PD-1 antibody, failed to show clinical benefits in PD-L1 positive EGFR-mutated NSCLC patients, even in those with a high expression of PD-L1 [33]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.